MA32785B1 - Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine - Google Patents
Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarineInfo
- Publication number
- MA32785B1 MA32785B1 MA33833A MA33833A MA32785B1 MA 32785 B1 MA32785 B1 MA 32785B1 MA 33833 A MA33833 A MA 33833A MA 33833 A MA33833 A MA 33833A MA 32785 B1 MA32785 B1 MA 32785B1
- Authority
- MA
- Morocco
- Prior art keywords
- digigatran
- etexilate
- classical
- salt
- treating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- 208000007536 Thrombosis Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 title 1
- 229960005080 warfarin Drugs 0.000 title 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000008602 contraction Effects 0.000 abstract 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 abstract 1
- 229960003850 dabigatran Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention porte sur un procédé de prévention d'un accident vasculaire cérébral chez un patient souffrant d'une fibrillation auriculaire, le patient ne présentant aucun facteur de risque vis-à-vis d'évènements d'hémorragie majeurs, le procédé consistant à administrer au patient 150 mg d'étexilate de dabigatran deux fois par jour, éventuellement sous la forme d'un sel pharmaceutiquement acceptable de celui-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11341308P | 2008-11-11 | 2008-11-11 | |
| US23755909P | 2009-08-27 | 2009-08-27 | |
| PCT/EP2009/064874 WO2010055022A1 (fr) | 2008-11-11 | 2009-11-10 | Procédé de traitement ou de prévention de thrombose à l'aide d'étexilate de dabigatran ou d'un sel de celui-ci avec une efficacité accrue par rapport à une thérapie classique par warfarine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32785B1 true MA32785B1 (fr) | 2011-11-01 |
Family
ID=41463075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33833A MA32785B1 (fr) | 2008-11-11 | 2011-05-11 | Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20110269799A1 (fr) |
| EP (1) | EP2355823A1 (fr) |
| JP (1) | JP2013510073A (fr) |
| KR (1) | KR20110082564A (fr) |
| CN (2) | CN103463083A (fr) |
| AR (1) | AR074107A1 (fr) |
| AU (1) | AU2009315730A1 (fr) |
| BR (1) | BRPI0921354A2 (fr) |
| CA (1) | CA2738884A1 (fr) |
| CL (1) | CL2011000806A1 (fr) |
| CO (1) | CO6382133A2 (fr) |
| EA (1) | EA201100755A1 (fr) |
| EC (1) | ECSP11011029A (fr) |
| IL (1) | IL211853A0 (fr) |
| MA (1) | MA32785B1 (fr) |
| MX (1) | MX2011004796A (fr) |
| NZ (1) | NZ592615A (fr) |
| PE (1) | PE20110432A1 (fr) |
| TN (1) | TN2011000227A1 (fr) |
| TW (1) | TW201031651A (fr) |
| WO (1) | WO2010055022A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110431A1 (es) | 2008-11-11 | 2011-07-13 | Boehringer Ingelheim Int | Etexilato de dabigatran o una sal del mismo |
| PL2550966T3 (pl) * | 2011-07-25 | 2017-03-31 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Estry kwasu amidooksymokarboksylowego dabigatranu jako proleki i ich zastosowanie jako lek |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| WO2014001220A1 (fr) | 2012-06-25 | 2014-01-03 | Boehringer Ingelheim International Gmbh | Procédé de prévention d'un accident vasculaire cérébral |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| WO2015071841A1 (fr) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| CN108254216B (zh) * | 2018-03-15 | 2021-04-27 | 攀钢集团西昌钢钒有限公司 | 一种高炉槽的矿料取样方法、装置及可读存储介质 |
| US12251377B2 (en) | 2019-03-06 | 2025-03-18 | University Of Rochester | Anticoagulant compositions and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| EP2043631A2 (fr) * | 2006-07-17 | 2009-04-08 | Boehringer Ingelheim International GmbH | Nouvelles indications portant sur les inhibiteurs directs de la thrombine dans le domaine cardiovasculaire |
-
2009
- 2009-11-10 MX MX2011004796A patent/MX2011004796A/es not_active Application Discontinuation
- 2009-11-10 KR KR1020117010632A patent/KR20110082564A/ko not_active Withdrawn
- 2009-11-10 TW TW098138140A patent/TW201031651A/zh unknown
- 2009-11-10 JP JP2011535125A patent/JP2013510073A/ja active Pending
- 2009-11-10 AR ARP090104347A patent/AR074107A1/es unknown
- 2009-11-10 BR BRPI0921354A patent/BRPI0921354A2/pt not_active IP Right Cessation
- 2009-11-10 CN CN2013102966233A patent/CN103463083A/zh active Pending
- 2009-11-10 PE PE2011001003A patent/PE20110432A1/es not_active Application Discontinuation
- 2009-11-10 EA EA201100755A patent/EA201100755A1/ru unknown
- 2009-11-10 US US13/128,460 patent/US20110269799A1/en not_active Abandoned
- 2009-11-10 CA CA2738884A patent/CA2738884A1/fr not_active Abandoned
- 2009-11-10 WO PCT/EP2009/064874 patent/WO2010055022A1/fr not_active Ceased
- 2009-11-10 AU AU2009315730A patent/AU2009315730A1/en not_active Abandoned
- 2009-11-10 NZ NZ592615A patent/NZ592615A/xx not_active IP Right Cessation
- 2009-11-10 CN CN2009801448169A patent/CN102209546A/zh active Pending
- 2009-11-10 EP EP09755873A patent/EP2355823A1/fr not_active Withdrawn
-
2010
- 2010-06-17 US US12/817,369 patent/US20100322870A1/en not_active Abandoned
-
2011
- 2011-03-22 IL IL211853A patent/IL211853A0/en unknown
- 2011-04-12 CL CL2011000806A patent/CL2011000806A1/es unknown
- 2011-05-04 EC EC2011011029A patent/ECSP11011029A/es unknown
- 2011-05-10 TN TN2011000227A patent/TN2011000227A1/fr unknown
- 2011-05-11 CO CO11058058A patent/CO6382133A2/es not_active Application Discontinuation
- 2011-05-11 MA MA33833A patent/MA32785B1/fr unknown
-
2012
- 2012-07-06 US US13/543,080 patent/US20120277269A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110082564A (ko) | 2011-07-19 |
| EA201100755A1 (ru) | 2011-12-30 |
| IL211853A0 (en) | 2011-06-30 |
| WO2010055022A1 (fr) | 2010-05-20 |
| EP2355823A1 (fr) | 2011-08-17 |
| BRPI0921354A2 (pt) | 2019-09-24 |
| US20110269799A1 (en) | 2011-11-03 |
| US20120277269A1 (en) | 2012-11-01 |
| CL2011000806A1 (es) | 2011-11-11 |
| TN2011000227A1 (en) | 2012-12-17 |
| NZ592615A (en) | 2013-06-28 |
| US20100322870A1 (en) | 2010-12-23 |
| AU2009315730A1 (en) | 2010-05-20 |
| MX2011004796A (es) | 2011-05-30 |
| CO6382133A2 (es) | 2012-02-15 |
| CN102209546A (zh) | 2011-10-05 |
| CA2738884A1 (fr) | 2010-05-20 |
| AR074107A1 (es) | 2010-12-22 |
| ECSP11011029A (es) | 2011-06-30 |
| JP2013510073A (ja) | 2013-03-21 |
| PE20110432A1 (es) | 2011-07-16 |
| CN103463083A (zh) | 2013-12-25 |
| TW201031651A (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32785B1 (fr) | Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine | |
| MA32786B1 (fr) | Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique | |
| EA200870424A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| EA200970933A1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
| TN2009000444A1 (en) | Combination therapy with a compound acting as a plateletadp receptor inhibitor | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| EP2178869A4 (fr) | Composés d'indole en tant qu'inhibiteurs de nécrose cellulaire | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| CY1112932T1 (el) | Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς | |
| CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
| PH12021551356A1 (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| TN2015000529A1 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| EA201101231A1 (ru) | Способы предотвращения или снижения риска смертности | |
| MA34547B1 (fr) | Traitement d'association pour traiter une infection par le vhc | |
| ZA202108034B (en) | Crystalline salt forms of a kinase inhibitor | |
| BR112022001270A2 (pt) | Compostos inibidores | |
| RU2011123367A (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином | |
| ATE551052T1 (de) | Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz | |
| MX2025002776A (es) | Formas solidas de un inhibidor de la proteina quinasa asociada a rho | |
| DK1784173T3 (da) | Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater | |
| WO2008016665A3 (fr) | Composés et méthodes de traitement de troubles médiés par flt3 | |
| TW200633692A (en) | Use of alpha-adrenergic blockers for the treatment of dysmenorrhea | |
| MA26796A1 (fr) | Derive d'aminotetraline pour la therapie des maladies cardiovasculaires. |